Please note: These studies may involve findings that exceed the claims currently cleared by the FDA for the product. Bravida Medical is not intending to make performance claims about its product. The intent is to disseminate the scientific literature on these products. We encourage you to read these studies to understand the strengths and limitations of the data. For some claims, Bravida is seeking to broaden the indications with the FDA in the future using data, such as these studies, to provide the substantiation.

Efficacy of Silver Plated Dressing Pad in Reducing Left Ventricular Assist Device Driveline Infections When Compared to **Chlorhexidine Impregnated Disc**

John De Pietro ANP, Jonathan Weber MPH, Rita Jermyn MD, Keri Messina NP, Kristin Rocco, NP, Noelle Fairchild PA- Jeremy A. Mazurek MD & Edward Lundy MD, PhD From the Center for Advanced Cardiac Therapeutics & Department of Cardiothoracic Surgery, St. Francis Hospital & Heart Center, Roslyn, NY

Subjects

N = 85 consecutive patients underwent LVAD (2017-

2024)

Background

- Driveline infections (DLIs) are the most frequent complication in the management of left ventricular assist device (LVAD) patients.
 - 32% infection rate after 6 months (STS **INTERMACS** database)
 - 21% infection rate over 5 years of follow-up (MOMENTUM 3 Trial)*

*Mehra, JAMA, 2022

Study Design/Hypothesis

- In a cohort of patients from a single center destination LVAD program we hypothesized changing the driveline dressing product and frequency of dressing change will decrease the incidence of DLIs when compared to the current protocol.
- From 2017 to 2022: all patients who underwent implantation of Heartmate II and Heartmate 3 LVADs were treated with chlorhexidine impregnated discs (CHG disc) applied three times weekly for driveline infection prevention.
- From June 2022-present: new implants received silver-plated pad (SSPD) for driveline site care applied weekly.
- Patients with prior implants were switched to weekly SSPD driveline site care.



 Chlorhexidine: N = 37 (44 	l%)
 SSPD: N = 23 (27%) 	
 Chlorhexidine to SSPD: N = 25 (29%) Table 1: Demographics & Medical History 	
Male gender	74 (87%)
Ethnicity	
White (non-Hispanic)	52 (61%)
Black (non-Hispanic	15 (18%)
Hispanic	14 (16%)
Asian	4 (5%)
Body mass index	31.1 ± 10
Prior cerebrovascular accidents	5 (6%)
Diabetes	24 (28%)
Chronic kidney disease	30 (35%)
NY Heart Association Class	4 (100%)
INTERMACS profile	
1	21 (25%)
2	9 (11%)
3	52 (61%)
4	3 (4%)
LVAD Pump Model	
HeartMate II	17 (20%)
HeartMate III	68 (80%)

Silver Plated

Dressing Pad

Chlorhexidine Disc



Disclosures: None Corresponding Author: John De Pietro NP St. Francis Hospital& Heart Center, Roslyn NY (516) 563-6000 John.DePietro@chsli.org



Results

Driveline Infections

After a mean of 36 ± 26 months of follow up, 9 patients developed a driveline infection.

- N = 7 cases of infection while using Chlorhexidine
- N = 2 cases of infection while using SSPD
- Incident risk ratio of 0.72 (95% CL 0.45 to 1.16) representing an overall 28% reduction in incidence of DLIs utilizing weekly SSPD

Figure 2. Incidence rate (per 1000 person-years) of driveline infections among LVAD patients 50

IRR 0.72 (0.45-1.16)



Conclusions

 Changing the driveline dressing protocol to silver plated dressing pad and reducing the frequency of the dressing change to once per week reduced the incidence of driveline infection by 28% when compared to the prior protocol.

 Further study will be required to determine is these results can be replicated in other centers.

son-years) 6

1000